Absci: $2.3B valuation, IPO Readiness 66, Series C. Generative AI drug design company using AI and cell biology to create better biologics faster. Track live on The IPO Stack.
Generative AI drug design company using AI and cell biology to create better biologics faster.
Scores, valuations, and IPO signals for the companies that matter. 5-minute read, every Tuesday.
Top companies most likely to IPO in 2026, ranked by IPO Readiness Score.
Track Absci IPO timeline, funding rounds, investor activity, and valuation on TechStackIPO — the pre-IPO intelligence platform.
Absci has not publicly announced IPO plans. Track TechStackIPO for the latest signals and subscribe to The IPO Stack for weekly updates.
Absci is valued at $2.3B as of May 2021. This valuation is based on its most recent private funding round tracked by TechStackIPO.
Accredited investors can access Absci shares through secondary market platforms, pre-IPO investment funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace tracks available access options. Note: pre-IPO investments carry higher risk and limited liquidity compared to public market investing.
Absci scores 66/100 (Grade: C) on TechStackIPO's IPO Readiness Index. The score evaluates funding scale, valuation trajectory, funding momentum, stage progression, and company maturity. Scores above 70 indicate strong near-term IPO potential.
Absci has raised $225M in total venture capital and private equity funding, with backing from NVIDIA, Foresite Capital, Leaps by Bayer.
Absci's notable investors include NVIDIA, Foresite Capital, Leaps by Bayer, Andreessen Horowitz, DCVC Bio. Full investor details, funding round history, and lead investor breakdowns are available on TechStackIPO.
Absci is a Biotechnology company. Generative AI drug design company using AI and cell biology to create better biologics faster.